# 4 Week 2 Way Crossover Double Blind Treatment Phase With Combivent CFC Versus Albuterol Followed by a 4 Week Open Label Combivent Respimat When All Drugs Are Used for Symptom Relief as Needed in Pts With Moderate to Severe Asthma

> **NCT00818454** · PHASE2 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 226 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Combivent CFC MDI
- **DRUG:** Albuterol HFA MDI
- **DRUG:** Respimat Combivent

## Key facts

- **NCT ID:** NCT00818454
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-12
- **Primary completion:** 2009-09
- **Final completion:** —
- **Target enrollment:** 226 (ACTUAL)
- **Last updated:** 2014-02-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00818454

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00818454, "4 Week 2 Way Crossover Double Blind Treatment Phase With Combivent CFC Versus Albuterol Followed by a 4 Week Open Label Combivent Respimat When All Drugs Are Used for Symptom Relief as Needed in Pts With Moderate to Severe Asthma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00818454. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*